RxDoctor Payments Data

Manooj Prasad, DPM

Foot & Ankle Surgery · Lakewood, NJNPI 1013107184

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,255 of the $15,735 with a category attached, or 65.2%. 48 manufacturers reported payments, led by Bone Support Inc. at 25.6% of the total. 2025 is the largest year on record at $5,124, 2.6 times the $1,947 reported in 2019. Among foot & ankle surgery clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$15,735in general payments, 2019–2025

Across 347 payments — averaging $45.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bone Support Inc.$4K
  • Amniox Medical, Inc.$2K
  • Musculoskeletal Transplant Foundation Inc.$1K
  • Organogenesis Inc.$1K
  • Smith+Nephew$1K
  • Stryker$657
  • plus $5K from 42 others

What the payments were for

  • Consulting fees$4,70030%
  • Travel & lodging$7805%
  • Food & beverage$10,25565%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,735 in reported general payments places this provider in the 90th percentile of 542 foot & ankle surgery providers in New Jersey.

See all foot & ankle surgery providers in New Jersey

Medicare billing

Part B allowed, 2024
$15,131,538
Medicare patients
295
Services billed
9,079

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.146$113,699
JubliaEfinaconazole12$15,400
Celecoxib24$548
Gabapentin35$476
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav38$396
Methylprednisolone16$148
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen20$119
CiclopiroxCiclopirox Olamine11$99
Clindamycin Hcl13$98
Terbinafine Hcl12$76

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$1,234$113,699146 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 542 foot & ankle surgery providers in New Jersey.

Other foot & ankle surgery in Lakewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →